BTIG analyst Julian Harrison raised the firm’s price target on Abivax (ABVX) to $150 from $120 and keeps a Buy rating on the shares. Abivax provided an updated 2026 pipeline outlook highlighting strong Phase 3 ABTECT induction data for obefazimod, positioning it as a preferred, flexible oral option across the moderate-to-severe treatment paradigm, with no new safety signals reported to date, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax SA: Strengthened Outlook for Obefazimod in IBD Drives Higher Target Price and Buy Rating
- – Abivax SA American Depositary Shares call volume above normal and directionally bullish
- Abivax rumored to attract interest from Eli Lilly, La Tribune says
- 5 Stocks That Moved the Most in 2025 – What Lies Ahead
- These Are the Most and Least Likely Biotech Takeover Targets for 2026